A Novel PCR-Based Methodology for Viral Detection Utilizing Mechanical Homogenization.
Coronavirus
Diagnostics
Homogenize
Infectious disease
Molecular diagnostics
PCR
RT-qPCR
Virology
Journal
Bio-protocol
ISSN: 2331-8325
Titre abrégé: Bio Protoc
Pays: United States
ID NLM: 101635102
Informations de publication
Date de publication:
05 Mar 2022
05 Mar 2022
Historique:
received:
05
01
2022
revised:
14
11
2021
accepted:
14
01
2022
entrez:
20
5
2022
pubmed:
21
5
2022
medline:
21
5
2022
Statut:
epublish
Résumé
The impact of viral diseases on human health is becoming increasingly prevalent globally with the burden of disease being shared between resource-rich and poor areas. As seen in the global pandemic caused by SARS-CoV-2, there is a need to establish viral detection techniques applicable to resource-limited areas that provide sensitive and specific testing with a logistically conscious mindset. Herein, we describe a direct-to-PCR technology utilizing mechanical homogenization prior to viral PCR detection, which allows the user to bypass traditional RNA extraction techniques for accurate detection of human coronavirus. This methodology was validated
Identifiants
pubmed: 35592597
doi: 10.21769/BioProtoc.4349
pii: e4349
pmc: PMC8918218
doi:
Types de publication
Journal Article
Langues
eng
Pagination
e4349Informations de copyright
Copyright © 2022 The Authors; exclusive licensee Bio-protocol LLC.
Déclaration de conflit d'intérêts
Competing interestsZPM, CMP, and RJN are named inventors on the patent describing this method held by Omni International, A PerkinElmer Company, but have no personal financial interests to disclose in the direct commercialization of this technology. CMP, GLR, and RJN are all full-time employees of Omni International Inc, A PerkinElmer Company, and GLR and RJN have no personal financial interests in the performance of the company. CMP is a shareholder of PerkinElmer, holding a personal financial interest in the performance of the company. ZPM is in a consulting relationship with Omni International, A PerkinElmer Company and holds no personal financial interests in the performance of the company. ZPM and RJN are also associated with Jeevan Biosciences LLC, a company which is not involved in the work described within this manuscript.
Références
PLoS One. 2021 Aug 18;16(8):e0256316
pubmed: 34407126
Virol J. 2020 Aug 25;17(1):129
pubmed: 32843049
Clin Microbiol Rev. 2000 Oct;13(4):559-70
pubmed: 11023957
Ann Intern Med. 2020 Jun 2;172(11):726-734
pubmed: 32282894
Int J Mol Sci. 2020 Apr 24;21(8):
pubmed: 32344568